Eledon Posts $69.7M Cash, Runway to Q2 2027 as Q3 Loss Widens Ex-Warrant Gain
ELDN sits 79% above its 52-week low of $1.35.
Summary
Eledon ended September 30 with $69.7M in cash, equivalents and short-term investments, down from $133.3M at December 31, 2025, and says that funds operations into Q2 2027. The Q3 net loss of $3.9M is flattered by a $17.0M non-cash warrant-liability gain; excluding it, the loss was $21.0M versus $18.0M a year earlier, with R&D spending up to $17.8M from $15.0M. The cash burn against a roughly $192M market cap makes the runway the number that matters here — the company has to raise money or deliver a partnering deal before mid-2027. On the clinical side, Eledon plans to start its Phase 3 kidney trial in Q4 2026, has FDA clearance for an islet-transplantation IND in type 1 diabetes, and holds Fast Track status for kidney transplant. Watch for the Phase 3 trial start in Q4 2026 and any financing announcement, since the 10-Q carries an explicit going-concern warning that funding runs short within twelve months.
At the time of this announcement, ELDN was trading at $2.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.2M. The 52-week trading range was $1.35 to $4.49. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.